Snap Inc vs Zimmer Biomet Holdings Inc — how do they compare? Snap Inc trades at $5.51 (market cap $9.05B), while Zimmer Biomet Holdings Inc trades at $97 (market cap $18.65B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 2.1× Snap Inc's market cap, and Zimmer Biomet Holdings Inc pays a 0.98% dividend while Snap Inc pays none. Which is the better fit depends on your goals.
| SNAP | ZBH | |
|---|---|---|
Market Cap | $9.05B | $18.65B |
Sector | Media | Health |
52-Week High | $9.09 | $107.71 |
52-Week Low | $3.93 | $79.58 |
Enterprise Value | $10.61B | $25.72B |
Dividend Yield | — | 0.98% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Zimmer Biomet (ZBH) trades at $96.55, down 0.66% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $103.56. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.07, and raised its full-year outlook. Revenue growth remains steady, supported by hips, specialty businesses, and technology, though net income margin has moderated from 2023 peaks. Recent corporate news includes a dividend declaration and expansion of its technology center in India.
The outlook for ZBH is positive, driven by consistent earnings beats and strategic growth initiatives, but investors face risks from margin pressure and increasing debt levels. The stock offers potential upside to the consensus target, supported by institutional accumulation, though competitive and macroeconomic headwinds in the medtech sector warrant caution.
Trailing returns across standard periods
Latest headlines on both assets
Snap, which refers to itself as a camera company, has one of the most popular social networking apps, Snapchat, in developed regions such as North America and Europe. The firm has approximately 158 million daily active users. Snap generates nearly all of its revenue from advertising with 88% coming from the U.S. The firm is headquartered in Venice, California.
Read more on SNAP →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →